Liposomal nanomedicines

DB Fenske, PR Cullis - Expert opinion on drug delivery, 2008 - Taylor & Francis
Liposomal nanoparticles (LNs) encapsulating therapeutic agents, or liposomal
nanomedicines, represent an advanced class of drug delivery systems, with several …

Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance

F Baquero, TM Coque… - Antimicrobial agents and …, 2011 - Am Soc Microbiol
In recent years, the explosive spread of antibiotic resistance determinants among
pathogenic, commensal, and environmental bacteria has reached a global dimension …

Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine

A Alshamsan, A Haddadi, V Incani… - Molecular …, 2009 - ACS Publications
This study was conducted to formulate a nonviral delivery system for the delivery of small
interfering RNA (siRNA) to B16 melanoma cells in vitro. For this purpose, oleic and stearic …

Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2

MMAK Shawan, AR Sharma, M Bhattacharya… - Infection, Genetics and …, 2021 - Elsevier
The devastating outbreak of COVID-19 has spread all over the world and has become a
global health concern. There is no specific therapeutics to encounter the COVID-19. Small …

MRNA therapy for Fabry disease

BC Guild, F DeRosa, M Heartlein - US Patent 9,308,281, 2016 - Google Patents
US9308281B2 - MRNA therapy for Fabry disease - Google Patents US9308281B2 - MRNA
therapy for Fabry disease - Google Patents MRNA therapy for Fabry disease Download PDF …

siRNA and RNAi optimization

A Alagia, R Eritja - Wiley Interdisciplinary Reviews: RNA, 2016 - Wiley Online Library
The discovery and examination of the posttranscriptional gene regulatory mechanism known
as RNA interference (RNAi) contributed to the identification of small interfering RNA (siRNA) …

MRNA therapy for phenylketonuria

F DeRosa, M Heartlein, A Dias - US Patent 9,522,176, 2016 - Google Patents
3,096.560 A 7, 1963 Liebig(PAH) at an effective dose and an administration interval
3,535,289 A 10, 1970 Yoshihara et al. such that at least one symptom or feature of PKU is …

Therapeutic uses of inhibitors of RTP801

E Feinstein, J Kaufmann, K Giese - US Patent 7,741,299, 2010 - Google Patents
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-
oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo …

Pulmonary delivery of mRNA

BC Guild, F DeRosa, M Heartlein - US Patent 9,597,413, 2017 - Google Patents
US9597413B2 - Pulmonary delivery of mRNA - Google Patents US9597413B2 - Pulmonary
delivery of mRNA - Google Patents Pulmonary delivery of mRNA Download PDF Info Publication …

Cftr mrna compositions and related methods and uses

M Heartlein, BC Guild, F DeRosa, C Rudolph… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
50513499&utm_source= google_patent&utm_medium= platform_link&utm_campaign …